Gain Therapeutics (NASDAQ:GANX) Now Covered by Analysts at Scotiabank
Scotiabank assumed coverage on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a sector outperform rating and a $12.00 target price on the stock. Several other analysts also recently issued reports on the company. Roth Mkm restated a “buy” rating and set […]
Scotiabank assumed coverage on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a sector outperform rating and a $12.00 target price on the stock. Several other analysts also recently issued reports on the company. Roth Mkm restated a “buy” rating and set […]
